Bibliography

Found 7 results

Filters: Keyword is Antiretroviral Therapy, Highly Active and Author is Letendre, S [Clear All Filters]

2019

Kallianpur AR, Gittleman H, Letendre S, Ellis R, Barnholtz-Sloan JS, Bush WS, Heaton R, Samuels DC, Franklin DR, Rosario-Cookson D, et al. Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection. Mol Neurobiol. 2019 ;56(5):3808-3818.

Perez-Valero I, Ellis RJ, Heaton RK, Deutsch R, Franklin D, Clifford DB, Collier AC, Gelman B, Marra C, McCutchan JA, et al. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. AIDS. 2019 ;33(3):475-481.

Livelli A, Vaida F, Ellis RJ, Ma Q, Ferrara M, Clifford DB, Collier AC, Gelman B, Marra CM, McArthur JC, et al. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV. 2019 ;6(7):e456-e462.

2015

Suh H-S, Lo Y, Choi N, Letendre S, Lee SC. Insulin-like growth factors and related proteins in plasma and cerebrospinal fluids of HIV-positive individuals. J Neuroinflammation. 2015 ;12:72.

2014

Grant I, Franklin D, Deutsch R, Woods SPaul, Vaida F, Ellis RJ, Letendre S, Marcotte TD, Atkinson JH, Collier AC, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 ;82(23):2055-62.

2013

Morgan EE, Woods SPaul, Letendre S, Franklin D, Bloss C, Goate A, Heaton RK, Collier AC, Marra CM, Gelman B, et al. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.

Bandaru VVenkata Ra, Mielke MM, Sacktor N, McArthur JC, Grant I, Letendre S, Chang L, Wojna V, Pardo C, Calabresi P, et al. A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology. 2013 ;81(17):1492-9.